Statin use and its association with musculoskeletal symptoms--a cross-sectional study in primary care settings

Moßhammer, Dirk; Lorenz, Gernot; Meznaric, S; Schwarz, Janina; Muche, Rainer; Mörike, Klaus

doi:10.1093/fampra/cmp006

Cited by 16 publications

(16 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in clinical practice, up to 10% of outpatients receiving statins report muscle pain [7–9]. German investigators sought to find an association between statin use and patient-reported musculoskeletal complaints (in patients ≥50 years of age) in a primary care setting while generating a logistic regression model with several covariates associated with such complaints [10]. Statin prescription versus no prescription was an independent variable associated with 1.5-fold odds of musculoskeletal complaints.…”

Section: Drugs Associated With Myotoxicitymentioning

confidence: 99%

Drug-related Myopathies of Which the Clinician Should Be Aware

Valiyil

Christopher‐Stine

2010

Curr Rheumatol Rep

View full text Add to dashboard Cite

Many drugs used for therapeutic interventions can cause unanticipated toxicity in muscle tissue, often leading to considerable morbidity. A drug-induced, or toxic, myopathy is defined as the acute or subacute manifestation of myopathic symptoms such as muscle weakness, myalgia, creatine kinase elevation, or myoglobinuria that can occur in patients without muscle disease when they are exposed to certain drugs. A brief review of agents with a known association with myotoxicity and the proposed mechanisms linked to that toxicity is outlined; however, the purpose of this review is to highlight recent discoveries and advances in the field of toxic myopathies that have practical implications for practicing physicians. Because many drug-related myopathies are potentially reversible at early stages, it is important for clinicians to recognize toxic myopathies early in their course to determine when to discontinue therapy and potentially prevent irreversible muscle damage.

show abstract

Section: Drugs Associated With Myotoxicitymentioning

confidence: 99%

Drug-related Myopathies of Which the Clinician Should Be Aware

Valiyil

Christopher‐Stine

2010

Curr Rheumatol Rep

View full text Add to dashboard Cite

show abstract

“…Although several studies from Western European countries described the clinical characteristics of muscle symptoms in their set of patients [16,[24][25][26][27], in Romania these data are missing as per our knowledge. The present study, although small in numbers, offers an insight into statin use in real clinical practice and its association with muscular symptoms.…”

Section: Discussionmentioning

confidence: 99%

An insight into statin use and its association with muscular side effects in clinical practice

Farcaş

Bucşa

Leucuţa

et al. 2015

Romanian Journal of Internal Medicine

View full text Add to dashboard Cite

show abstract

“…With regard to simvastatin, the risk factors for myopathy are presented in Table 1 [16][17][18] . The Epidata 3.1 ® program was used to organise the data.…”

Section: Artigos Originais -Promoção Da Saúdementioning

confidence: 99%

Muscle Adverse Events Among Users of Simvastatin in Primary Health Care: Collaborative Drug Therapy Management

Lobrigatte

Nogueira²,

Navarini

et al. 2018

SaudPesq

View full text Add to dashboard Cite

Collaborative drug therapy management in primary health care involves communication among the physician, pharmacist and user of simvastatin and can result in safer results regarding patient wellbeing. The aim of the study was to investigate muscle adverse events and risk factors related to simvastatin. For patients who developed muscle adverse events, collaborative drug therapy management was performed in an attempt to resolve the symptoms. A non-randomized case study was conducted at the single basic health unit in the city of Peabiru, Parana, Brazil, for a period of one year. Patients were interviewed using a structured form. To confirm muscle adverse events, the patient was referred to a physician and submitted to the suspension and return to treatment. Thyroid-stimulating hormone, creatine kinase and alanine aminotransferase exams were performed. A sample of 148 users of simvastatin was selected. Eleven patients had some type of simvastatinassociated muscle adverse event (myopathy), among whom seven had muscle symptoms (myalgia) and four had elevated creatine kinase, but were asymptomatic (asymptomatic myopathy). Collaborative drug therapy management focused on simvastatin for five patients with myalgia led to improvements in the quality of life of two patients. EVENTOS ADVERSOS MUSCULARES ENTRE USUÁRIOS

show abstract

Statin use and its association with musculoskeletal symptoms--a cross-sectional study in primary care settings

Abstract: Having a statin prescription appears to be an independent factor associated with musculoskeletal symptoms in primary care settings. Statin use may be more often associated with musculoskeletal complaints than previously assumed.

Cited by 16 publications

References 20 publications

Drug-related Myopathies of Which the Clinician Should Be Aware

Drug-related Myopathies of Which the Clinician Should Be Aware

An insight into statin use and its association with muscular side effects in clinical practice

Muscle Adverse Events Among Users of Simvastatin in Primary Health Care: Collaborative Drug Therapy Management

Contact Info

Product

Resources

About